CN109789088A - 新制剂 - Google Patents

新制剂 Download PDF

Info

Publication number
CN109789088A
CN109789088A CN201780060340.5A CN201780060340A CN109789088A CN 109789088 A CN109789088 A CN 109789088A CN 201780060340 A CN201780060340 A CN 201780060340A CN 109789088 A CN109789088 A CN 109789088A
Authority
CN
China
Prior art keywords
zinc
insulin
concentration
preparation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780060340.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·格林
S·豪威尔
J·耶热克
L·扎克热夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1616509.4A external-priority patent/GB201616509D0/en
Priority claimed from GBGB1617866.7A external-priority patent/GB201617866D0/en
Priority claimed from GBGB1707190.3A external-priority patent/GB201707190D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CN109789088A publication Critical patent/CN109789088A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159Dose expelling manners
    • A61M5/31591Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159Dose expelling manners
    • A61M5/31593Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780060340.5A 2016-09-29 2017-09-29 新制剂 Pending CN109789088A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1616509.4 2016-09-29
GBGB1616509.4A GB201616509D0 (en) 2016-09-29 2016-09-29 Novel formulations
GB1617866.7 2016-10-21
GBGB1617866.7A GB201617866D0 (en) 2016-10-21 2016-10-21 Novel formulations
GB1707190.3 2017-05-05
GBGB1707190.3A GB201707190D0 (en) 2017-05-05 2017-05-05 Novel Formulations
PCT/GB2017/052941 WO2018060736A1 (en) 2016-09-29 2017-09-29 Novel formulations

Publications (1)

Publication Number Publication Date
CN109789088A true CN109789088A (zh) 2019-05-21

Family

ID=60037644

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780060340.5A Pending CN109789088A (zh) 2016-09-29 2017-09-29 新制剂
CN201780060339.2A Active CN109803639B (zh) 2016-09-29 2017-09-29 新制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780060339.2A Active CN109803639B (zh) 2016-09-29 2017-09-29 新制剂

Country Status (13)

Country Link
US (2) US20190282667A1 (enExample)
EP (3) EP3518892B1 (enExample)
JP (5) JP7145849B2 (enExample)
KR (1) KR102482664B1 (enExample)
CN (2) CN109789088A (enExample)
AU (2) AU2017334290B2 (enExample)
CA (2) CA3034971C (enExample)
DK (1) DK3518892T5 (enExample)
ES (1) ES2954180T3 (enExample)
IL (1) IL265609B2 (enExample)
MX (1) MX2019003611A (enExample)
PL (1) PL3518892T3 (enExample)
WO (2) WO2018060735A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206391A (zh) * 2019-08-09 2022-03-18 艾瑞克有限公司 包含抗体的新组合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US20190282667A1 (en) * 2016-09-29 2019-09-19 Arecor Limited Novel formulations
GB201707188D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
JP7465813B2 (ja) * 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム
US20210113763A1 (en) * 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7728176B2 (ja) * 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
JP7518149B2 (ja) * 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
WO2022157747A2 (en) * 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
CN103930096A (zh) * 2011-10-31 2014-07-16 Xeris药物公司 用于治疗糖尿病的制剂
CN104994864A (zh) * 2012-12-19 2015-10-21 沃克哈特有限公司 包含人胰岛素或其类似物或衍生物的稳定水性组合物
WO2016100042A1 (en) * 2014-12-16 2016-06-23 Eli Lilly And Company Rapid-acting insulin compositions
CN105899191A (zh) * 2014-01-09 2016-08-24 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
ES2072596T3 (es) 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN101340893B (zh) * 2005-10-20 2012-03-21 玛瑞纳生物技术有限公司 速效胰岛素的鼻内施用
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
CA2743725A1 (en) * 2006-06-23 2007-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
HUE027239T2 (en) 2009-06-26 2016-10-28 Novo Nordisk As Preparation containing insulin, nicotinamide and arginine
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
SG11201604706TA (en) * 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
GB201607918D0 (en) * 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US20190282667A1 (en) * 2016-09-29 2019-09-19 Arecor Limited Novel formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
CN103930096A (zh) * 2011-10-31 2014-07-16 Xeris药物公司 用于治疗糖尿病的制剂
CN104994864A (zh) * 2012-12-19 2015-10-21 沃克哈特有限公司 包含人胰岛素或其类似物或衍生物的稳定水性组合物
CN105899191A (zh) * 2014-01-09 2016-08-24 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
WO2016100042A1 (en) * 2014-12-16 2016-06-23 Eli Lilly And Company Rapid-acting insulin compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张石革等: "胰岛素及胰岛素类似物的进展与应用", 《中国药业》 *
王理群等: "胰岛素给药新剂型研究进展", 《中国医药工业杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206391A (zh) * 2019-08-09 2022-03-18 艾瑞克有限公司 包含抗体的新组合物

Also Published As

Publication number Publication date
CA3034972A1 (en) 2018-04-05
EP3518892A1 (en) 2019-08-07
IL265609B1 (en) 2023-10-01
ES2954180T3 (es) 2023-11-20
IL265609B2 (en) 2024-02-01
WO2018060736A1 (en) 2018-04-05
KR20190060788A (ko) 2019-06-03
JP2024153677A (ja) 2024-10-29
US20190282667A1 (en) 2019-09-19
AU2017334289B2 (en) 2023-04-20
DK3518892T3 (da) 2023-07-31
EP4265296A2 (en) 2023-10-25
PL3518892T3 (pl) 2023-11-27
AU2017334290B2 (en) 2023-04-20
CA3034971C (en) 2025-07-08
EP4265296A3 (en) 2023-12-20
EP3518892B1 (en) 2023-06-21
JP2022180499A (ja) 2022-12-06
IL265609A (en) 2019-05-30
CN109803639A (zh) 2019-05-24
AU2017334290A1 (en) 2019-03-21
EP3518893A1 (en) 2019-08-07
AU2017334289A1 (en) 2019-03-21
CA3034971A1 (en) 2018-04-05
WO2018060735A1 (en) 2018-04-05
CN109803639B (zh) 2024-01-02
DK3518892T5 (da) 2024-09-02
MX2019003611A (es) 2019-06-17
US20190290737A1 (en) 2019-09-26
JP2022176989A (ja) 2022-11-30
JP2019533656A (ja) 2019-11-21
CA3034972C (en) 2024-04-09
JP2019529506A (ja) 2019-10-17
KR102482664B1 (ko) 2022-12-29
JP7145849B2 (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
CN109789088A (zh) 新制剂
CN109069590A (zh) 包含聚山梨酯80的胰岛素制剂
CN110582285B (zh) 稳定的胰岛素制剂
US20200222508A1 (en) Glucagon-like peptide 1 (glp-1) receptor agonist compositions
KR102833828B1 (ko) 인슐린 화합물의 전달을 위한 의료용 주입 펌프 시스템
CN112040928A (zh) 用于递送胰岛素化合物的医用输注泵系统
JP2020518636A (ja) 新規の製剤
CN111989088A (zh) 用于递送胰岛素化合物的医用输注泵系统

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Saffron Walden, England

Applicant after: Arecor Ltd.

Address before: British county

Applicant before: Arecor Ltd.

CB02 Change of applicant information